Pfizer To Acquire FoldRx Pharmaceuticals

FoldRx Focused on First-in-Class, Disease-Modifying, Oral Therapeutics to Treat Diseases Caused by Protein Misfolding

Lead Product Candidate, Tafamidis, in Registration in the European Union as First-in-Class Oral Therapy for Transthyretin Amyloid Polyneuropathy (ATTR-PN)

 

New York, N.Y., and Cambridge, MA, September 1

Pfizer Inc. (NYSE: PFE) and FoldRx Pharmaceuticals, Inc., a privately held drug discovery and clinical development company, today announced that they have entered into an agreement under which Pfizer will acquire FoldRx.

Click here to read FoldRx's news release.